Skip to main content

Advertisement

Table 4 Univariate response analysis of metagenes stratified by subtype

From: Dual roles for immune metagenes in breast cancer prognosis and therapy prediction

Variable a Odds ratio P -value
(95% CI)
Basal-like n = 205 (pr = 72, nr = 133)
 B/P 1.26 (0.95-1.68) 0.12
 T/NK 1.53 (0.93-2.51) 0.09
 M/D 1.66 (1.15-2.39) 0.007
Claudin-low n = 47 (pr = 17, nr = 30)
 B/P 1.92 (1.10-3.34) 0.02
 T/NK 2.08 (0.80-5.47) 0.14
 M/D 1.11 (0.43-2.86) 0.82
HER2-E n = 72 (pr = 26, nr = 46)
 B/P 1.31 (0.84-2.04) 0.23
 T/NK 0.83 ( 0.36-1.92) 0.67
 M/D 1.19 (0.54-2.59) 0.67
LumB n = 133 (pr = 23, nr = 110)
 B/P 1.33 (0.93-1.89) 0.11
 T/NK 1.44 ( 0.86-2.42) 0.16
 M/D 1.71(1.01-2.91) 0.05
LumA n = 207 (pr = 7, nr = 200)
 B/P 1.52 (0.82-2.83) 0.19
 T/NK 1.16 (0.52-2.60) 0.72
 M/D 0.93 (0.43-2.02) 0.85
  1. B/P = B cells/plasma B cells; CI = confidence interval; HER2-E, HER2-enriched; LumA = Luminal A; LumB = Luminal B; M/D = monocyte/dendritic cell population; T/NK = T cell/natural killer cell-specific population.
  2. aFor each subtype, 'n' is the number of cases, 'pr' is the number of responders, and 'nr' is the number of nonresponders.